Literature DB >> 26035588

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

Gary A Ulaner1, Debra A Goldman1, Craig S Sauter1, Jocelyn Migliacci1, Joshua Lilienstein1, Mithat Gönen1, Heiko Schöder1, Craig H Moskowitz1, Andrew D Zelenetz1.   

Abstract

PURPOSE: To determine the prognostic value of performing fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) before allogeneic and autologous stem cell transplantation (SCT) in patients with aggressive lymphoma.
MATERIALS AND METHODS: A HIPAA-compliant retrospective review was performed under institutional review board waiver. Patients with aggressive lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010. FDG PET/CT was performed within the 3 months prior to transplantation. PET/CT images were evaluated for lesions with FDG avidity greater than that of the background liver. The relationship between pretransplantation PET and progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test for categorical variables and Cox regression for continuous variables.
RESULTS: A total of 175 patients were identified, of whom 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT. Before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions. For allogeneic SCT, the 2-year PFS estimate was 68% (95% confidence interval [CI]: 56%, 82%) in patients without FDG-avid lesions, but only 35% (95% CI: 20%, 61%) for patients with FDG-avid lesions (P = .014). For autologous SCT, the 2-year PFS was 72% (95% CI: 64%, 82%) in patients without FDG-avid lesions, but only 18% (95% CI: 5%, 64%) for patients with FDG-avid lesions (P < .0001). Similar differences were seen in OS and DSS. The risk for posttransplantation recurrence correlated with higher lesional maximum standardized uptake values: for PFS, P < .0001 to P = .01; for DSS, P < .0001 to P = .002; and for OS, P < .0001 to P = .015.
CONCLUSION: Performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic value. For patients with aggressive lymphomas, the presence of FDG-avid lesions at PET/CT performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success. © RSNA, 2015

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26035588      PMCID： PMC5006668          DOI： 10.1148/radiol.2015142556

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  18 in total

1.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

Authors:  Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Peter Vandenberghe; Johan Maertens; Guy Bormans; José Thomas; Jan Balzarini; Christine De Wolf-Peeters; Luc Mortelmans; Gregor Verhoef
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

2.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

3.  Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.

Authors:  J Svoboda; C Andreadis; R Elstrom; E A Chong; L H Downs; A Berkowitz; S M Luger; D L Porter; S Nasta; D Tsai; A W Loren; D L Siegel; E Glatstein; A Alavi; E A Stadtmauer; S J Schuster
Journal:  Bone Marrow Transplant       Date:  2006-06-12       Impact factor: 5.483

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

6.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

Review 7.  Interim PET-CT in the management of diffuse large B-cell lymphoma.

Authors:  Craig H Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

8.  Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

Authors:  Jonathan R Lambert; Jamshed B Bomanji; Karl S Peggs; Kirsty J Thomson; Ronjon K Chakraverty; Adele K Fielding; Panagiotis D Kottaridis; Michael Roughton; Emma C Morris; Anthony H Goldstone; David C Linch; Peter J Ell; Stephen Mackinnon
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

9.  Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

Authors:  Elias Jabbour; Chitra Hosing; Gregory Ayers; Rodolfo Nunez; Paolo Anderlini; Barbara Pro; Issa Khouri; Anas Younes; Fredrick Hagemeister; Larry Kwak; Luis Fayad
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

10.  Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.

Authors:  Craig S Sauter; Lauren Lechner; Michael Scordo; Junting Zheng; Sean M Devlin; Stephen E Fleming; Hugo Castro-Malaspina; Craig H Moskowitz
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-15       Impact factor: 5.742
View more
  8 in total

1.  Reaching 200-ps timing resolution in a time-of-flight and depth-of-interaction positron emission tomography detector using phosphor-coated crystals and high-density silicon photomultipliers.

Authors:  Sun Il Kwon; Alessandro Ferri; Alberto Gola; Eric Berg; Claudio Piemonte; Simon R Cherry; Emilie Roncali
Journal:  J Med Imaging (Bellingham)       Date:  2016-11-23

2.  Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

Authors:  M Lia Palomba; Joachim Yahalom; Brandon S Imber; Michel Sadelain; Carl DeSelm; Connie Batlevi; Renier J Brentjens; Parastoo B Dahi; Sergio Giralt; Jae H Park; Craig Sauter; Michael Scordo; Gunjan Shah; Miguel-Angel Perales
Journal:  Br J Haematol       Date:  2020-03-05       Impact factor: 6.998

3.  Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.

Authors:  Lisa Giulino-Roth; Tara O'Donohue; Zhengming Chen; Tanya M Trippett; Elizabeth Klein; Nancy A Kernan; Rachel Kobos; Susan E Prockop; Andromachi Scaradavou; Neerav Shukla; Peter G Steinherz; Alison J Moskowitz; Craig H Moskowitz; Farid Boulad
Journal:  Leuk Lymphoma       Date:  2017-11-29

4.  Prognostic value of pre-transplantation total metabolic tumor volume on 18fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in relapsed and refractory aggressive lymphoma.

Authors:  Takeshi Sugio; Shingo Baba; Yasuo Mori; Goichi Yoshimoto; Kenjiro Kamesaki; Shuichiro Takashima; Shingo Urata; Takahiro Shima; Kohta Miyawaki; Yoshikane Kikushige; Yuya Kunisaki; Akihiko Numata; Katsuto Takenaka; Hiromi Iawasaki; Toshihiro Miyamoto; Kousei Ishigami; Koichi Akashi; Koji Kato
Journal:  Int J Hematol       Date:  2022-06-14       Impact factor: 2.319

5.  Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation.

Authors:  Yun Soo Park; Seok Mo Lee; Ji Sun Park; Sang Kyun Bae; Hye-Kyung Shim; Won-Sik Lee; Sang-Min Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-11-21

Review 6.  Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma.

Authors:  Eva González-Barca; Mónica Coronado; Alejandro Martín; Carlos Montalbán; Santiago Montes-Moreno; Carlos Panizo; Guillermo Rodríguez; Juan Manuel Sancho; Andrés López-Hernández
Journal:  Oncotarget       Date:  2018-08-17

7.  Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.

Authors:  Na Dai; Hang Liu; Shengming Deng; Shibiao Sang; Yiwei Wu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

8.  Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience.

Authors:  Rabia Wali; Haleema Saeed; Naveed Patrus; Shehla Javed; Saadiya Javed Khan
Journal:  J Glob Oncol       Date:  2019-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.